Weekly Recap | NMTC.US -12.81%, consensus target well above spotWeekly Review·Aug 29 at 06:06 AMNMTC0.00%
NeuroOne Medical Technologies shares are trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.benzinga_article·Aug 27 at 02:03 PMNMTC0.00%
NeuroOne reports successful large-animal procedures using next-generation StereoCED platformPUBT·Aug 27 at 01:06 PMNMTC0.00%
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline UpsideTip Ranks·Aug 18 at 06:47 PMNMTC0.00%
Niche Tech and Specialized Equities Show Divergent Mid-2026 MetricsGlobal Report·Aug 18 at 09:43 AMABEV0.00%NMTC0.00%
Anthony Vendetti Maintains Buy on NeuroOne, Reaffirms $5 Price Target on Growing Product Momentum and Diversified Neuro Ablation PipelineTip Ranks·Aug 15 at 11:45 AMNMTC0.00%
NeuroOne (NMTC) Fiscal Q3 2026 Earnings Call: Orders Rise 43%, Margin Reaches 59.9%TradingKey·Aug 14 at 08:32 AMNMTC0.00%
NMTC: Q3 FY2026 delivered 16% revenue growth, 59.9% gross margin, and key milestones for global expansionQuartr·Aug 13 at 01:39 PMNMTC0.00%
NeuroOne Fiscal Q3 2026 Earnings: Gross Margin Expands as Net Loss WidensTradingKey·Aug 13 at 12:12 PMNMTC0.00%
NeuroOne Medical Market Development Director Mark Christianson sells 10,000 shares for $31,773PUBT·Jul 2 at 08:41 PMNMTC0.00%
